Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.leu.2404944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing.
Bioorg Chem
January 2025
Molecular Toxicology Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore 641046, India. Electronic address:
Tyrosine kinase inhibitors (TKIs) represent a pivotal class of targeted therapies in oncology, with multiple generations developed to address diverse molecular targets. Imatinib is the first TKI developed to target the BCR-ABL1 chimeric protein, which is the key driver oncogene implicated in Philadelphia chromosome-positive chronic myeloid leukemia (CML). Several second-generation tyrosine kinase inhibitors (2GTKIs), such as nilotinib, dasatinib, bosutinib, and radotinib (RTB), followed the groundbreaking introduction of imatinib.
View Article and Find Full Text PDFDispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater.
Daru
December 2024
Department of Chemistry, Ilam Branch, Islamic Azad University, Ilam, Iran.
Article Synopsis
- Nilotinib is a medicine used to treat a type of leukemia called chronic myelogenous leukemia (CML), and it’s really important to keep track of its levels in patients and the environment.
- The study developed a new method using special materials called MOFs to find nilotinib in both blood and wastewater samples.
- The results showed that this new method worked well, especially with one of the MOFs, making it easier and faster to test for nilotinib levels.
Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 2: Experimental validation of the models of expansion, post-expansion mechanical strength, and drug release.
Int J Pharm
June 2024
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
In Part 1, we have introduced expandable gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. The expansion rate, post-expansion mechanical strength, and drug release rate were modeled for a dosage form containing 200 mg nilotinib. In the present part, the dosage form was prepared and tested in vitro to validate the models.
View Article and Find Full Text PDFComparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Clin Lymphoma Myeloma Leuk
June 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Peking University People's Hospital, Qingdao, China.. Electronic address:
Article Synopsis
- A study was conducted to compare therapy responses and outcomes among four medications (nilotinib, dasatinib, flumatinib, and imatinib) for newly diagnosed chronic myeloid leukemia (CML) in a practical setting.
- Data from 2,496 patients across 77 centers in China were analyzed, and results showed that the newer treatments had similar effectiveness in terms of overall survival and progression-free survival, but better initial responses and failure-free survival compared to imatinib.
- The findings suggest that while nilotinib, dasatinib, and flumatinib are more effective in achieving early treatment responses, all four medications ultimately offer comparable long-term survival outcomes, which can help
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.
Hematol Rep
November 2023
HTA Unit, Regional Health Care System, Regione Toscana, 50139 Firenze, Italy.
In Philadelphia chromosome-positive B-cell (Ph+) acute lymphoblastic leukemia (LLA), growing evidence has accumulated regarding the efficacy of low-intensity and chemo-free regimens. Our objective was to analyze all recent trials evaluating these treatments and to compare them in terms of efficacy. We applied the Shiny method, an artificial intelligence technique, to analyze Kaplan-Meier curves and reconstruct patient-level data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!